American Pharmaceutical company Pfizer has recently published a call to action to diversify clinical trials participation. They are addressing so-called “underrepresented” populations, ranging from communities of color to the elderly, rural populations, or other socioeconomic categories negatively correlating with clinical trial participation. Clinical trials are incredibly important: they represent a fundamental basis for the founding of TrialSite News and the media platform's mission to help bring more transparency, and associated accessibility to research, to more people around the world. That requires trust, which necessitates as much objectivity as humanly possible. It’s working; our traffic has grown in such a short time and will approach 1 million per month sometime in 2020. But that’s just the start. As Pfizer identifies, distrust runs deep and often is associated with health systems themselves. Socioeconomic and cultural forces interplay to influence social and health care outcomes: hence the emergence of social determinants of health as a broad-based conversation.
Why is Diversity Needed in Clinical Trials?
Because the development of new drugs and therapies may im...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).